H-FLLPTGAEA-OH

Ref. 3D-PP48478

Informations sur le produit

• Nom: H-FLLPTGAEA-OH

Description

Peptide H-FLLPTGAEA-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-FLLPTGAEA-OH include the following: Differential ion mobility spectrometry coupled to tandem mass spectrometry enables targeted leukemia antigen detection U Dharmasiri, SL Isenberg , GL Glish - Journal of Proteome , 2014 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/pr500527c A novel HLA-A* 0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia M Zhang, P Sukhumalchandra, AA Enyenihi - Clinical Cancer , 2013 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/19/1/247/77989 A Novel HLA-A2 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target for Myeloid Leukemia M Zhang, P Sukhumalchandra, AA Enyenihi, LSS John - Blood, 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119609158 Cathepsin G is expressed by acute lymphoblastic leukemia and is a potential immunotherapeutic target M Khan, S Carmona, P Sukhumalchandra - Frontiers in , 2018 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2017.01975/full Alkali Metal Cationization of Tumor-associated Antigen Peptides for Improved Dissociation and Measurement by Differential Ion Mobility-Mass Spectrometry JE Keating, C Chung, S Chai , JF Prins - Journal of proteome , 2020 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.jproteome.0c00157 Targeting Myeloid Leukemia Using Novel TCR-like Chimeric Antigen Receptor-T Cells Against Cathepsin G J Yan, Z Tian, C Shi, M Zhang, P Sukhumalchandra - Blood, 2022 - ashpublications.orghttps://ashpublications.org/blood/article/140/Supplement%201/7392/492101 Characterization of CBX-250, a first-in-class TCR-mimetic-based T-cell engager targeting a cathepsin G peptide-HLA complex for the treatment of myeloid leukemia G Paulus, B Lee, P Sankaran, T Rahman, J Jimenez - Cancer Research, 2024 - AACRhttps://aacrjournals.org/cancerres/article/84/6_Supplement/1236/739282 Cathepsin G Is Broadly Expressed By AML and Is an Effective Immunotherapeutic Target Against AML in Vivo G Alatrash , M Zhang, P Sukhumalchandra, Y Qiu - Blood, 2014 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119726731 Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target G Alatrash , HR Garber, M Zhang, P Sukhumalchandra - Leukemia, 2017 - nature.comhttps://www.nature.com/articles/leu2016249 Tumor-associated antigens G Alatrash , AK Crain, JJ Molldrem - Immune biology of allogeneic , 2019 - Elsevierhttps://www.sciencedirect.com/science/article/pii/B9780128126301000074 Targeting cathepsin G in myeloid leukemia G Alatrash - Oncoimmunology, 2013 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.4161/onci.23442 AML Immunotherapy Using a Novel Tcrm-Based Bispecific Antibody That Targets a Leader Sequence Peptide Derived from Cathepsin G C Shi, Z Tian, J Yan, M Zhang, P Sukhumalchandra - Blood, 2023 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497123080187

• Marque: Biosynth